Jean-Jacques Bienaimé, BioMarin CEO
August 1, 2023 11:39 AM EDT
Pharma
Manufacturing

Bio­Marin touts Vox­zo­go sales bump in Q2 re­sults, notes 'tem­porar­i­ly tight sup­ply'

Tyler Patchen

News Reporter

Bio­Marin is tout­ing “record rev­enues” from the first half of 2023, spear­head­ed by the jump in sales of its achon­dropla­sia drug Vox­zo­go — so much so …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times